T18	Exp 133 145	The capacity
T19	Exp 232 234	We
T20	Exp 502 506	when
T21	Exp 485 496	both groups
T22	Exp 695 707	The addition
T23	Exp 792 807	both cell types
T24	Exp 1052 1054	we
T25	Exp 1280 1282	we
T26	Exp 1069 1094	its nuclear translocation
T27	Exp 1020 1031	the control
T28	Exp 1131 1171	the electrophoretic mobility shift assay
T29	Exp 1250 1264	the activation
T30	Exp 1346 1383	the ROI-reactive fluorochrome DCFH-DA
T31	Exp 1328 1339	these cells
T32	Exp 1705 1714	the cells
T33	Exp 1764 1775	Our results
T34	Exp 1784 1788	that
T35	Exp 1907 1911	that
T36	Exp 1957 1994	the ROI-NF-kappa B signalling pathway
T37	Exp 1912 1928	these activators
R2	Coref Anaphora:T26 Antecedent:T38
T1	Protein 8 12	CD28
T2	Protein 21 34	interleukin-2
T3	Protein 177 190	interleukin-2
T4	Protein 192 196	IL-2
T5	Protein 244 248	IL-2
T6	Protein 419 423	CD28
T7	Protein 470 474	IL-2
T8	Protein 575 579	IL-2
T9	Protein 665 669	IL-2
T10	Protein 716 720	CD28
T11	Protein 773 777	IL-2
T12	Protein 823 827	IL-2
T13	Protein 1035 1039	IL-2
T14	Protein 1559 1563	CD28
T15	Protein 1748 1752	IL-2
T16	Protein 1797 1801	IL-2
T17	Protein 1877 1881	CD28
T38	Exp 971 981	NF-kappa B
